


CASE REPORT

Open Access



# Gastric inflammatory myofibroblastic tumor: a case report

Taku Hattori<sup>1</sup>, Yutaka Tanizawa<sup>1\*</sup> , Tadakazu Shimoda<sup>2</sup>, Yusuke Koseki<sup>1</sup>, Kenichiro Furukawa<sup>1</sup>, Keiichi Fujiya<sup>1</sup>, Daisuke Aizawa<sup>2</sup>, Takashi Sugino<sup>2</sup>, Masanori Terashima<sup>1</sup> and Etsuro Bando<sup>1</sup>

## Abstract

**Background** Inflammatory myofibroblastic tumor (IMT) of the stomach is an uncommon mesenchymal neoplasm. We present a case of gastric submucosal tumor (SMT) where the final diagnosis was IMT.

**Case presentation** A 69-year-old man presented with a 24-mm SMT on the posterior wall of the middle third of the stomach that was detected by screening upper gastrointestinal endoscopy. Abdominal contrast-enhanced computed tomography showed that the tumor was well-enhanced. Although endoscopic ultrasonography-guided biopsy was performed, the histological diagnosis was not confirmed preoperatively. Since the tumor was clinically suspected to be a gastrointestinal stromal tumor, we performed gastric wedge resection by laparoscopic–endoscopic cooperative surgery. Pathologically, proliferative spindle cells with a positive reaction for smooth muscle actin, negativity for c-kit, desmin, s-100, CD34, STAT-6,  $\beta$ -catenin and anaplastic lymphoma kinase 1 were identified. Hence, the tumor was finally diagnosed as an IMT originating from the stomach.

**Conclusions** When an SMT of the stomach is identified, the possibility of gastric IMT should be considered.

**Keywords** Inflammatory myofibroblastic tumor, Stomach, Submucosal tumor, Gastric tumor

## Background

Inflammatory myofibroblastic tumor (IMT) is classified as an intermediate malignant neoplasm by the World Health Organization Histological Typing of Soft Tissue Tumors [1]. IMT of the stomach is an extremely rare tumor of uncertain etiology with a variety of clinical features, which makes it difficult to diagnose preoperatively. Here, we present a case of primary gastric IMT, along with a review of the relevant literature.

## Case presentation


A 69-year-old man presented with an asymptomatic gastric submucosal tumor (SMT) that was detected by screening upper gastrointestinal endoscopy at another hospital. Contrast-enhanced chest and abdominal computed tomography (CT) showed a mass on the gastric wall and a tumor in the right lung. Thoracoscopic partial resection of the right lung was first performed for diagnosis and treatment of the lung tumor, and the resected specimen was pathologically suspected as being a metastatic lung tumor from thyroid papillary carcinoma. He was referred to our hospital for further examination and treatment for thyroid cancer and the gastric SMT. Evaluation of the gastric SMT by upper gastrointestinal endoscopy at our hospital revealed a flat protrusion without surface ulceration on the posterior wall of the middle third of the stomach (Fig. 1). Contrast-enhanced abdominal CT demonstrated a well-enhanced solid mass at the greater curvature of the stomach, measuring 22×18 mm (Fig. 2). Endoscopic ultrasonography

\*Correspondence:


Yutaka Tanizawa  
y.tanizawa@scchr.jp

<sup>1</sup> Divisions of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan

<sup>2</sup> Divisions of Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan




**Fig. 1** Upper gastrointestinal endoscopy. **A** Conventional endoscopy. **B** Narrow-band imaging endoscopy. Upper gastrointestinal endoscopy revealed the submucosal mass as a flat protrusion on the posterior wall of the middle third of the stomach



**Fig. 2** Abdominal enhanced computed tomography. **A** Horizontal view. **B** Coronal view. Abdominal enhanced CT scan showed a contrast-enhanced round mass on the posterior wall of the stomach (yellow arrows), with no evidence of tumor metastasis

(EUS) showed a hypoechoic mass, 22 mm in diameter, arising from the muscularis propria layer (Fig. 3). Endoscopic ultrasonography-guided fine needle aspiration (FNA) identified spindle cell nests with inflammation of the stomach. Immunohistochemically, the spindle cells were partially positive for alpha smooth muscle actin (ASMA) and desmin, but negative for c-kit, CD34, discovered on GIST-1 (DOG1) and S-100. Although he was diagnosed as having a gastrointestinal tumor of the stomach, the preoperative histological diagnosis was inconclusive. At the same time, contrast-enhanced neck CT showed a nodule-aggregating lesion with calcification in the right lobe of the thyroid gland, and enlarged

regional lymph nodes. He was diagnosed with papillary thyroid carcinoma and cervical lymph node metastasis by neck ultrasonography-guided biopsy. Thus, we planned to first perform surgery for the thyroid malignancy, followed by partial gastric resection. Histopathological evaluation of the resected specimen obtained by total thyroidectomy with radical cervical lymph node resection, performed by the department of head and neck surgery at our hospital, confirmed the diagnosis. Subsequently, we performed gastric wedge resection of the gastric SMT by laparoscopic–endoscopic cooperative surgery. Macroscopic evaluation of the gastric tumor showed a circular tumor, measuring 35×25×15 mm,




**Fig. 3** Endoscopic ultrasonography. Endoscopic ultrasonography demonstrated a hypoechoic mass, 22 × 20 mm in diameter (yellow arrows). The white arrows indicate the muscularis propria layer

with a whitish cut surface. The tumor invaded the muscular layer of the gastric wall, and the surgical margin was negative (Fig. 4). Microscopic examination revealed

well-circumscribed, spindle-shaped tumor cells, consisting of fibroblasts, myofibroblasts and eosinophils, accompanied by myxoid changes and collagen fibers mainly in the stroma, and identified in the gastric wall from the lamina propria to the intrinsic muscularis (Fig. 5). There was no atypia, necrosis, nuclear fission, or calcification. On immunohistochemical evaluation, the spindle cells showed positive immunoreactivity for ASMA and partial positivity for calponin, but negativity for anaplastic lymphoma kinase-1 (ALK-1), S-100, desmin D33, c-kit, CD34, DOG1, CD56, and  $\beta$ -catenin, while the IgG4/IgG ratio was 10–20% and Ki-67 labeling index was 10–20% (Fig. 6). The final diagnosis was consistent with an IMT originating from the stomach. The patient was uneventfully discharged from the hospital on postoperative day 7, and no recurrence of IMT was observed on CT at 29 months after surgery.


### Discussion

IMT was first reported in two cases of benign pulmonary spindle cell tumors by Brunn [2] in 1939. It usually involves the lung and occurs in children and young adults [3]. It is currently classified as an intermediate neoplasm according to the World Health Organization Histological




**Fig. 4** **A, B** Macroscopically, the tumor presented as a 15 mm, round nodule, with a yellowish-white cut surface. **C** The tumor consisted of spindle cells spreading from the submucosal layer to the muscularis propria layer (Hematoxylin–eosin staining,  $\times 1$ ). **D** The spindle cells showed negative staining for anti-desmin antigen ( $\times 1$ )





**Fig. 5** Pathological evaluation of the tumor (Hematoxylin–eosin staining,  $\times 20$ ). **A** The mass was characterized by spindle cell proliferation. **B** The stroma was infiltrated by inflammatory cells. **C** Spindle cell tumors extended into the subserosal layer



**Fig. 6** Immunohistochemical staining of the tumor ( $\times 40$ ). **A, B** The tumor cells were slightly positive for ASMA (**A**) and CD34 (**B**). **C, D** They were completely negative for STAT6 (**C**) and c-kit (**D**). **E, F** They were positive for CD79a (**E**) and CD3 (**F**)

Typing of Soft Tissue Tumors [1]. Although its etiology and pathogenesis are still controversial, the development of IMT has been hypothesized to be affected by many causes, such as infection, trauma, surgery, autoimmunity, and chromosomal variation of the ALK gene [4]. Distant

metastasis of this tumor is rare, occurring in 5% of cases. The most common sites of metastases are the lung and brain, followed by the liver and bone [5].

Making an accurate preoperative diagnosis of IMT is difficult. Patients with IMT sometimes present anemia

on laboratory analyses, although there are no characteristic findings for IMT on CT and EUS. Hence, most IMT cases require surgical exploration to obtain an accurate microscopic diagnosis [4]. Complete resection has been proposed as the treatment of this tumor since residual tumor can cause local recurrence. However, the optimal surgical extent and approach are unclear [1, 3]. The recurrence rate after resection is ~ 25% [1], with most cases showing local recurrence.

Pathologically, IMT is composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes and eosinophils, and usually occurs in the soft tissue and viscera. Immunohistochemically, the spindle cells are reactive against antibodies to vimentin and ASMA [6]. Furthermore, rearrangements of the ALK gene on chromosome 2p23 are suggested in the pathogenesis of IMT [7]. Three architectural patterns for IMT have been described: myxoid hypocellular pattern; a cellular fascicular or nested pattern with variable amounts of myxoid stroma; and a sclerotic, hyalinized pattern with minimal myxoid stroma. However, these patterns are often admixed in a single tumor [3]. There are no requirements for the diagnosis on pathological examination. It is only after other mesenchymal tumors have been ruled out that a definitive diagnosis is made.

Since only few reviews have provided detailed reports of the clinicopathological features of gastric IMT, we conducted a review of 41 clinical cases associated with gastric IMT that were resected surgically or endoscopically by performing a search of the PubMed database. The details of these cases, including the present case, are shown in Tables 1 and 2 [8–42].

Median patient age was 42 years, and the number of women was 24 (58.5%). In terms of clinical manifestations, abdominal pain was recognized in 20 cases (48.8%), followed by anemia, weight loss, nausea, and vomiting. Tumors were mostly located in the body of the stomach (in 29 cases, 70.7%), and mainly on the posterior wall, followed by the greater and lesser curvatures. Synchronous metastases of seed nodules in the small intestine and greater omentum were seen in only one case, and six cases (14.6%) exhibited direct infiltration of the spleen, pancreas, left diaphragm, esophagus, and hilum of the left lung. Although biopsy was performed preoperatively in 16 cases (39.0%), only two cases (4.9%) were diagnosed as gastric IMT, both of which were diagnosed in the same institution and had a high degree of invasion. Most cases were misdiagnosed as gastrointestinal stromal tumor (GIST). Eighteen cases had iodine-induced contrast effects on enhanced CT imaging. The median tumor size was 55 mm, and the intraluminally growing type was recognized in 20 cases (48.8%). Tumors with calcification

**Table 1** Clinical findings in 41 cases of gastric IMT

Clinical findings	No. of patients	
	(n = 41)	[%]
Age (y.o)		
Range	0–80	
Median	42	
Sex		
Male	17	[42]
Female	24	[59]
Symptom		
Abdominal pain	20	[49]
Anemia	14	[34]
Body weight loss	10	[24]
Abdominal discomfort	4	[10]
Gastrointestinal bleeding	4	[10]
Malaise	4	[10]
Fever (BT > 37.0 °C)	2	[5]
Gastroesophageal reflux	2	[5]
Dysphagia	1	[2]
Coma	1	[2]
Syncope	1	[2]
No complaint	1	[2]
NA	3	[7]
Preoperative diagnosis		
IMT	2	[5]
GIST	8	[20]
Ectopic pancreas	2	[5]
Gastric polyp	1	[2]
Gastric hemangioma	1	[2]
Gastric leiomyoma	1	[2]
Gastric cancer	1	[2]
Gastric teratoma	1	[2]
Gastric myoma	1	[2]
Mucinous cystic neoplasm	1	[2]
Adrenal neuroblastoma	1	[2]
NA	21	
Site of synchronous metastasis		
Greater omentum	1	[2]
Small intestine	1	[2]
Treatment		
Partial gastrectomy	23	[56]
Distal gastrectomy	6	[15]
Proximal gastrectomy	6	[15]
Total gastrectomy	3	[7]
Gastrectomy with other organ resection	8	[20]
EMR	2	[5]
ESD	1	[2]
Tumor size from the specimen (mm)		
Range	15–220	
Median	55	

NA not available, Hb hemoglobin, BT body temperature, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection



**Table 2** Endoscopic and CT imaging findings in 41 cases of gastric IMT

Characteristics of endoscopy and CT image	No. of patients	
	(n = 41)	[%]
Tumor localization (length axis)		
Cardia	6	[15]
Body	29	[71]
Pylorus	3	[7]
NA	3	[7]
Tumor localization (short axis)		
Greater curvature	9	[22]
Lesser curvature	7	[17]
Anterior wall	5	[12]
Posterior wall	13	[32]
NA	7	[17]
Direction of tumor growth		
Intraluminally	19	[46]
Extraluminally	11	[27]
Intra and extraluminally	9	[22]
NA	2	[5]
Site of infiltration		
Spleen	3	[7]
Pancreas	2	[5]
Left diaphragm	1	[2]
Liver	1	[2]
Esophagus	1	[2]
Lung	1	[2]
CT enhancement		
Heterogeneously enhanced	12	[29]
Homogeneously enhanced	4	[10]
None or hypointense	6	[15]
NA	19	[46]
Tumor with calcification		
Positive	4	[10]
Negative	30	[73]
NA	7	[17]
Tumor with ulceration		
Positive	16	[39]
Negative	20	[49]
NA	5	[12]

were recognized in four cases (9.8%), and ulceration was seen in 16 cases (39.0%).

Partial gastrectomy was performed in 24 cases (58.5%), distal gastrectomy and proximal gastrectomy in six cases each (14.6%), and total gastrectomy in three cases (7.3%). In all cases, spindle tumor cells were identified immuno-histochemically. In addition, the cells were positive for ALK in 13 cases (31.7%), for ASMA in 32 cases (78.0%), and for vimentin in 23 cases (56.1%) (Fig. 7). On the other


hand, the tumors stained negatively for Epstein–Barr virus (EBV)-determined nuclear antigen, latent membrane protein-1 (LMP-1), and EBV-encoded small RNA in all six of the cases evaluated. In contrast with GIST, none of these tumors was positive for c-kit or DOG1, and fewer of them stained positive for CD34 (3 cases, 7.3%). Recurrence was observed in only two cases (4.9%), the site of which was the remnant stomach and the small intestine. The above observations showed that gastric IMT has a lot in common with IMT occurring in other organs. However, there is no specific clinical feature to identify IMT from among gastric SMTs.

In our case, the patient was relatively older, and the tumor was smaller compared to previous reports. In addition, our case had no symptoms, as was seen in only one case in the previous literature. We assumed that our case had no symptoms because of the small tumor size, which prevented from being identified earlier.

FNA is usually performed in the preoperative diagnostic work-up of gastric SMT. Only the cellular components are extracted by FNA, as opposed to the entire tissue by surgical specimen. For this reason, it is often difficult to determine tumor or non-tumor and to reach a definitive diagnosis, especially for mesenchymal tumors. Surgical treatment for diagnostic purposes was selected because biopsies had already been done for three specimens, and Japanese practice guidelines for GIST state that an SMT of 2–5 cm in size is a relative indication for resection [43, 44].

Positive surgical margins are the most common causes of local recurrence, which is the most common type of recurrence, according to previous IMT reports [1]. Although several reports suggested that the anatomic site of IMT is associated with the recurrence rate [1], there are no detailed reports of postoperative recurrence of primary gastric IMT. In the present review, two cases showed recurrence. One patient had local recurrence after partial gastrectomy, splenectomy, and omentectomy with a positive resection margin on the peritoneum. Another patient had a small bowel stricture due to peritoneal recurrence after proximal gastrectomy, partial diaphragmectomy, and partial left pneumonectomy. Although ALK reactivity was found to be associated with local recurrence [2], our review did not find evidence for this connection. In addition, though 26 of the 41 patients (63.4%) underwent partial resection of the stomach, not a single recurrence occurred at the remnant stomach. Consequently, it was considered unlikely that local excision would lead to a positive resection margin and further local recurrence.

As in other cases, partial gastrectomy was performed for diagnosis and treatment. In particular, laparoscopic–endoscopic cooperative surgery is beneficial because it



**Fig. 7** Immunohistochemical findings in 41 cases of gastric IMT. *EBV* Epstein–Barr virus, *ALK* anaplastic lymphoma kinase, *ASMA* alpha smooth muscle actin, *DOG* discovered on GIST, +: positive, -: negative

allows evaluation of tumor progression and safe resection of the margin of the tumor, particularly in cases that are undiagnosed preoperatively.

Conclusions

Gastric IMT is a rare mesenchymal tumor with uncertain physical and inspection findings. Our experience suggests that IMT should be considered in the differential diagnosis of gastric SMTs, which may contribute to the safe and complete resection.

Abbreviations

IMT	Inflammatory myofibroblastic tumor
SMT	Submucosal tumor
CT	Computed tomography
EUS	Endoscopic ultrasonography
FNA	Fine needle aspiration
ASMA	Alpha smooth muscle actin
DOG	Discovered on GIST
ALK	Anaplastic lymphoma kinase
EBV	Epstein–Barr virus
NA	Not available
Hb	Hemoglobin
BT	Body temperature
EMR	Endoscopic mucosal resection
ESD	Endoscopic submucosal dissection

Acknowledgements

Not applicable.

Author contributions

YT designed the report and wrote the manuscript. TS pathologically diagnosed the disease and suggested the differential diagnosis. All authors read and approved the final manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The data supporting the conclusions of this case report are included within the article.

Declarations

Ethics approval and consent to participate

This present study was approved by the institutional review board of Shizuoka Cancer Center (approval no. 2023-164-2023-1-2).

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare no competing interests and did not receive support for the submitted work from any organization.

Received: 16 November 2023 Accepted: 13 February 2024

Published online: 15 March 2024

References

- Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumour. In: Fletcher CD, Unni KK, Mertens F, editors. World health organization of classification of tumors: pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 91–3.
- Brunn H. Two interesting benign lung tumors of contradictory histopathology. *J Thorac Surg.* 1939;9:119–31.
- Katakwar A, Gedam BS, Mukewar S, Agasti A. Primary gastric inflammatory myofibroblastic tumor in an adult case report with brief review. *Indian J Surg Oncol.* 2014;5(1):66–70.

4. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? *J Clin Pathol*. 2008;6:428–37.
5. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. *Am J Surg Pathol*. 2007;31:509–20.
6. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. *Am J Surg Pathol*. 1995;19:859–72.
7. Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. *Am J Surg Pathol*. 2001;25:1364–71.
8. Greenston JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. *Mod Pathol*. 2003;16:366–75.
9. Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Başsorgun ÇI, et al. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. *Case Rep Oncol Med*. 2013;2013:328108.
10. Uno H, Takahara Y, Nishida T, Ohno T, Komatsu T. A case of laparoscopic local resection of the stomach for an inflammatory myofibroblastic tumor. *Gan To Kagaku Ryoho*. 2019;46:2054–6.
11. Chen WC, Jiang ZY, Zhou F, Wu ZR, Jiang GX, Zhang BY, et al. A large inflammatory myofibroblastic tumor involving both stomach and spleen: a case report and review of the literature. *Oncol Lett*. 2015;9:811–5.
12. Mirshemirani A, Tabari AK, Sadeghian N, Shariat-Torbaghan S, Pourafkari M, Mohajerzadeh L. Abdominal inflammatory myofibroblastic tumor: report on four cases and review of literature. *Iran J Pediatr*. 2011;21:543–8.
13. Fan J, Huang B, Yang X, Yang M, He J, Nie X. ALK-positive gastric inflammatory myofibroblastic tumor in an adult with familial adenomatous polyposis and diffuse fundic polyposis. *Diagn Pathol*. 2017;12:68.
14. Lee D, Suh YL, Lee SK. Calcifying fibrous pseudotumour arising in a gastric inflammatory myofibroblastic tumour. *Pathology*. 2006;38:588–91.
15. Shin HC, Gu MJ, Kim SW, Kim JW, Choi JH. Coexistence of gastrointestinal stromal tumor and inflammatory myofibroblastic tumor of the stomach presenting as a collision tumor: first case report and literature review. *Diagn Pathol*. 2015;10:181.
16. He J, Zhao X, Huang C, Zhou X, You Y, Zhang L, et al. Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm. *Cancer Biol Ther*. 2018;19:967–72.
17. Hatlani MA, Ratcliffe EM. Endoscopic visualization of a gastric polypoid mass: a rare pediatric presentation of an inflammatory myofibroblastic tumor. *Gastrointest Endosc*. 2010;71:894–5.
18. Shah SM, Sussman D, Jorda M, Ribeiro A. EUS with EMR of an inflammatory myofibroblastic tumor of the stomach. *Gastrointest Endosc*. 2008;67:561–3.
19. Park SH, Kim JH, Min BW, Song TJ, Son GS, Kim SJ, et al. Exophytic inflammatory myofibroblastic tumor of the stomach in an adult woman: a rare cause of hemoperitoneum. *World J Gastroenterol*. 2008;14:136–9.
20. Cho MY, Min YK, Kim NR, Cho SJ, Kim HK, Lee KC, et al. Fever of unknown origin as a presentation of gastric inflammatory myofibroblastic tumor in a two-year-old boy. *J Korean Med Sci*. 2002;17:699–703.
21. Costa JE, Correia-Pinto J, Rodrigues FC, Carvalho JL, Campos M, Dias JA, et al. Gastric inflammatory myofibroblastic proliferation in children. *Pediatr Surg Int*. 1998;13:95–9.
22. Riedel BD, Wong RC, Ey EH. Gastric inflammatory myofibroblastic tumor (inflammatory pseudotumor) in infancy: case report and review of the literature. *J Pediatr Gastroenterol Nutr*. 1994;19:437–43.
23. Albayrak F, Dursun H, Albayrak Y, Altas S, Uyanik A, Yildirim R. Inflammatory myofibroblastic tumor of the stomach in an adult woman: a rare intermittent cause of gastric outlet obstruction. *Tumori*. 2010;96:492–5.
24. Ning X, Liang B, Liu Q, Chen X, Xu M. Gastric inflammatory myofibroblastic tumor identified as ectopic pancreas and treated by endoscopic submucosal dissection. *Gastrointest Endosc*. 2017;86:921–2.
25. Prillwitz OM, Hurtado BP, Álvarez SO, Sánchez NMA, Palomino REA. Gastric inflammatory myofibroblastic tumor in a 10-month-old girl: a case report. *Int J Surg Case Rep*. 2020;68:185–9.
26. Fong AK, Teoh AY, Chiu PW, Wong SK, Ng EK. Gastric inflammatory myofibroblastic tumor masquerading as a pancreatic cystic neoplasm. *Endoscopy*. 2010;42:231–2.
27. Hayashi M, Kawakubo H, Mayanagi S, Nakamura R, Suda K, Wada N, et al. Gastric inflammatory myofibroblastic tumor treated with combined laparoscopic and endoscopic gastric wedge resection: a case report. *World J Surg Oncol*. 2018;16:161.
28. Lazure T, Ferlicot S, Gauthier F, Doze F, Couturier J, Fabre M, et al. Gastric Inflammatory myofibroblastic tumors in children: an unpredictable course. *J Pediatr Gastroenterol and Nutr*. 2002;34:319–22.
29. Paris-Sans M, Domènech-Calvet J, Raga-Carceller E, Sabench-Pereferreb F, Daniel del I Castillo-Déjardin DD. Gastric inflammatory myofibroblastic tumour as a rare cause of biliary duct obstruction. *Cir Esp*. 2016;94:188–90.
30. Qiu JF, Shi YJ, Fang L, Wang HF, Zhang MC. High fever as an initial symptom of primary gastric inflammatory myofibroblastic tumor in an adult woman. *Int J Clin Exp Med*. 2014;7:1468–73.
31. Jadhav M, Harvi R, Patil R, Kittur S. Inflammatory myofibroblastic tumor of the Stomach presenting as an exophytic mass—a diagnostic dilemma. *Turk Patoloji Derg*. 2019;35:151–6.
32. Leon CJ, Castillo J, Mebold J, Cortez L, Felmer R. Inflammatory myofibroblastic tumor of the stomach: an unusual complication after gastrectomy. *Gastrointest Endosc*. 2006;63:347–9.
33. Kim DJ, Kim W. Inflammatory myofibroblastic tumor treated with laparoscopic proximal gastrectomy and double-tract anastomosis. *J Gastric Cancer*. 2015;15:64–7.
34. Lee YK, Wang HY, Shyung LR, Chang CW, Chen MJ. Inflammatory myofibroblastic tumor: an unusual submucosal lesion of the stomach. *Endoscopy*. 2011;43:151–2.
35. Noh BJ, Min JW, Sung JY, Park YK, Lee J, Kim YW. Inflammatory myofibroblastic tumor-like stromal proliferation within gastric inverted hyperplastic polyp. *Pathol Int*. 2016;66:180–2.
36. Shi H, Wei L, Sun L, Guo A. Primary gastric inflammatory myofibroblastic tumor: a clinicopathologic and immunohistochemical study of 5 cases. *Pathol Res Pract*. 2010;206:287–91.
37. Katakwar A, Gedam BS, Mukewar S, Agasti A. Primary gastric inflammatory myofibroblastic tumor in an adult- case report with brief review. *Indian J Surg Oncol*. 2014;5:66–70.
38. Chong A, Ha JM, Hong R, Park SG, Lee HJ. Inflammatory myofibroblastic tumor mimicking gastric gastrointestinal stromal tumor on 18F-FDG PET/CT. *Clin Nucl Med*. 2014;39:725–7.
39. Hajong R, Newme K, Khongwar D. Primary inflammatory myofibroblastic tumor of stomach-report of a very rare case. *J Family Med Prim Care*. 2021;10:552–3.
40. Bjelovic M, Micev M, Spica B, Babic T, Gunjic D, Djuric A, et al. Primary inflammatory myofibroblastic tumor of the stomach in an adult woman: a case report and review of the literature. *World J Surg Oncol*. 2013;1:1–6.
41. Ribeiro MCB, Lopes LR, Neto JCS, Meirelles LR, de Carvalho RB, Andreollo NA. Rare gastric inflammatory myofibroblastic tumor in an adult woman: a case report with review of the literature. *Case Rep Med*. 2012;2012:374070.
42. Hamidah A, Khu SY, Thambidorai CR, Muhaizan WM, Zarina AL, Jamal R. Recurrent gastric inflammatory myofibroblastic tumour in a 13-year-old male. *Pediatr Surg Int*. 2007;23:601–3.
43. Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. *Int J Clin Oncol*. 2008;13:416–30.
44. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. *Gastric Cancer*. 2016;19:3–14.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.